2013-02-26 07:32:31 -
Medigene AG /
Medigene's Veregen® Included in European Treatment Guideline for the Management
of Anogenital Warts
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, February 26 2013. Medigene AG (Frankfurt, Prime Standard)
announced today that Veregen(®) was included into the 2012 European Guideline
for the Management of Anogenital Warts. This internationally accepted treatment
guideline, developed by clinical experts, recommends Veregen(®) (Sinecatechins
10% & 15% ointment) as a treatment option for genital warts. The guideline will
be published in the March 2013 edition of the "Journal of the European Academy
of Dermatology and Venereology"(*), and is already available online. The
inclusion of Veregen(®) into the treatment guidelines in other countries is in
preparation.
Since 2010, Veregen(®) (Sinecatechins 15% ointment) has
also been recommended as
a treatment option for genital warts in the US Department of Health and Human
Services Center for Disease Control and Prevention's Sexually Transmitted
Diseases Treatment Guidelines.
"We are pleased that Veregen(® )is being endorsed as an efficacious and safe
treatment in both the US and the European treatment guidelines. These guidelines
represent an important source of key information for physicians for the
treatment of this extremely onerous sexually transmitted disease", commented Dr.
Frank Mathias, CEO of Medigene AG.
About Veregen(®): Veregen(®) is a topical treatment for external genital warts,
which contains a concentrate of catechins with a complex defined composition
extracted from green tea leaves. Veregen(®) is already marketed in the USA (by
Fougera), Germany, Austria and Switzerland (by Abbott), and Spain (by Bial).
Marketing authorizations in additional countries have been granted or are
expected within the next few months. Medigene has entered into several marketing
partnerships for Veregen across Europe, Asia, and America, and is planning to
continue this global licensing strategy to further exploit the market potential
of Veregen(®).
Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene was the first German biotech company to have revenues from
marketed products, which are distributed by partner companies. It has two drug
candidates in clinical trials, EndoTAG(®)-1 and RhuDex(®), and is developing an
innovative vaccine technology. For more information, please visit
www.medigene.com.
*Journal of the European Academy of Dermatology and Venerology, Volume 27, Issue
3, March 2013, Pages e263-e270, C.J.N. Lacey, S.C.Woodhall, A.Wikstrom and
J.Ross
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) and Veregen(®) are registered trademarks of Medigene AG. Polyphenon
E(® )is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or
licensed in select locations only.
Contact
Julia Hofmann, Claudia Burmester
Investor & Public Relations
ph.: +49 - 89 - 20 00 33 - 33 01
email:
investor@medigene.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF:
hugin.info/132073/R/1680865/549282.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via Thomson Reuters ONE
[HUG#1680865]
